Form D · Biotechnology
Orbsen Therapeutics Ltd.
Galway, L2 · CIK 0001712617
Offering snapshot reported Jul 26, 2017 · SEC filing
- Reported sold
- $1.26M Offering amount: $3.69M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jan 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 26, 2017 | Initial | $1,257,491 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-291532
All USD amounts calculated using average conversion rate of GBP at initial closing.
Source: Form D, filed Jul 26, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Francis Barry | Director, Executive |
| Chris Coughlan | Director |
| Larry Couture | Director, Executive |
| Gerry Cuddy | Director |
| Jim Fahy | Director |
| Jack Kavanaugh | Director |
| Timothy O'brien | Director |
| Scott Tornblom | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Orbsen Building National University Of Ireland, Galway
Galway, L2, H91DK59
Galway, L2, H91DK59